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Summary
Background: Appropriate levels of skeletal muscle tone are
needed to support routine motor behaviors. But, the brain
mechanisms that function to couple muscle tone with waking
behaviors are unknown.We addressed this question by study-
ing mice with cataplexy—a condition caused by a decoupling
of motor and arousal behaviors. Cataplexy is characterized by
involuntary loss of muscle tone during wakefulness, which
results in postural collapse during otherwise normal con-
sciousness. Cataplexy is caused by loss of hypocretin (orexin)
cells, but it is unknown how this loss triggers motor inactivity
during cataplexy. Here, we used hypocretin knockout mice
to identify the neurochemical cause of cataplexy and to deter-
mine the biochemical mechanisms that normally function to
couple arousal and motor systems.
Results: Using genetic, behavioral, electrophysiological, and
pharmacological approaches, we show that the noradrenergic
system acts to synchronize motor and arousal systems. Spe-
cifically, we show that an excitatory noradrenergic drive main-
tains postural muscle tone during wakefulness by activating a1
receptors on skeletal motoneurons. Loss of this normal excit-
atory drive triggers motor inactivity during cataplexy by
reducing motoneuron excitation. However, loss of this drive
does not affect arousal since mice remain awake during cata-
plexy, suggesting the noradrenergic system is not required for
maintaining wakefulness. Artificial restoration of noradren-
ergic drive to motoneurons prevents motor inactivity and res-
cues cataplexy.
Conclusions:We conclude that hypocretin deficiency causes
cataplexy by short-circuiting the noradrenergic drive to skel-
etal motoneurons. We suggest that the noradrenergic system
functions to couple the brain systems that control postural
muscle tone and behavioral arousal state.
Introduction
A generalized level of postural muscle tone is required to sup-
port waking behaviors. During active wakefulness, high levels
of muscle tone function to maintain routine body postures
such as sitting or standing. The importance of postural tone
becomes immediately apparent as soon as it is lost. Becoming
‘‘weak with laughter’’ or ‘‘weak at the knees’’ are common
expressions that illustrate the impact ofmuscle tone on normal
behaviors. Despite its importance, the mechanisms that func-
tion to match postural muscle tone with wakefulness remain
undetermined.
Under rare conditions, arousal state and motor activity
decouple. Opossums will voluntarily immobilize themselves*Correspondence: john.peever@utoronto.cato escape predation. While ‘‘playing dead,’’ they are function-
ally paralyzed but behaviorally alert [1]. A similar but involun-
tary phenomenon known as cataplexy occurs in humans.
During cataplexy, muscle paralysis (atonia) overwhelms the
skeletal motor system, leaving the affected individual awake
but either fully or partially immobilized [2–4]. Cataplexy is
therefore a useful experimental model for understanding how
the central nervous system (CNS) couples motor activity and
behavior state. Although cataplexy results from loss of hypo-
cretin cells, it is unclear how this causes cataplexy.
The noradrenergic system is thought to play an important
role in coupling muscle tone with behavioral state. Noradren-
ergic cells project to brain structures that mediate both behav-
iors, and their direct stimulation can facilitate muscle tone and
arousal state [5–8]. Noradrenergic cells also discharge in a
pattern that implies they synchronize these behaviors. Locus
coeruleus (LC) cells fire maximally during waking, when
postural tone is highest, and minimally during sleep when it
is lowest [4, 9]. However, a landmark study found that norad-
renergic cells stop firing during cataplexywhen consciousness
is preserved but motor tone is minimal [4]. These observations
sparked the long-standing—but untested—hypothesis that
noradrenergic system inactivity causes cataplexy.
We used a mouse model of cataplexy [10, 11] to determine
whether loss of noradrenergic drive is its root cause. First,
we found that cataplexy attacks are sensitive to changes in
noradrenergic system activity. We showed that increased
noradrenergic drive prevents cataplexy, whereas decreased
drive exacerbates it. Second, we demonstrate that cataplexy
is caused by loss of noradrenergic drive to motoneurons—
i.e., the cells that directly support muscle tone. During normal
wakefulness, noradrenergic drive supports postural tone by
activatinga1 receptors onmotoneurons. But, during cataplexy,
this excitatory drive is lost, in turn triggeringmotor paralysis by
reducing a1-receptor-driven motoneuron activation. Finally,
we show that restoration of noradrenergic drive to motoneu-
rons rescues muscle paralysis during cataplexy. We conclude
that cataplexy is caused by loss of the noradrenergic drive that
functions to promote waking muscle tone. The noradrenergic
system therefore functions to ensure that postural muscle
tone is appropriately matched to arousal state.
Results
Cataplexy Results from Decoupling of Motor and Arousal
Systems
Cataplexy is a chief symptom of narcolepsy—a sleep disorder
marked by abnormal rapid eye movement (REM) sleep control
[3]. Genetic deletion of the hypocretin gene (hypocretin
knockout mice) causes a behavioral phenotype that mimics
human narcolepsy, including episodes of cataplexy. Here,
we used hypocretin knockout mice to determine whether
changes in noradrenergic system function are responsible,
either in whole or part, for triggering cataplexy.
We used both behavioral and electrophysiological criteria to
characterize and identify cataplexy episodes and typical
sleep-wake states. Narcoleptic mice (n = 8) experienced mul-
tiple episodes of cataplexy during the recording period (i.e.,
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Figure 1. Masseter Muscles Experience Atonia during Cataplexy
(A) Example EEG and EMG (neck andmasseter) traces showing loss of skel-
etal muscle tone during an episode of cataplexy in a hypocretin knockout
mouse.
(B) Group data showing that neck and masseter muscle tone are lost during
cataplectic attacks. EMG tone was elevated during waking periods before
and after each attack but was minimal during cataplexy.
(C) EEG and EMG traces demonstrating that muscle tone reached similar
levels during REM sleep and cataplexy.
(D) Group data (n = 8) showing that levels of muscle tone were comparable
during REM sleep and cataplexy. This observation demonstrates that
masseter and neck muscles experience muscle atonia during cataplexy.
*p < 0.001. A.U., arbitrary units. Values are plotted asmeans + SEM. See also
Movie S1 for a visual demonstration of cataplexy.
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Figure 2. Cataplexy Is Sensitive to Changes in Noradrenergic Tone
(A and B) Systemic administration of a a1 receptor agonist (5 and 10 mg/kg
phenylephrine) decreased cataplexy by reducing the number of cataplexy
episodes.
(C and D) Systemic administration of a a1 antagonist (5 and 10mg/kg terazo-
sin) increased the number of cataplexy attacks.
*p < 0.05. Values are plotted as means + SEM.
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172019:00 hr–01:00 hr). Cataplexy occurred exclusively during
active wakefulness and was characterized by abrupt behav-
ioral arrest and postural collapse (Movie S1 available online).
During each episode, electromyographic (EMG) tone de-
creased while electroencephalographic (EEG) activity re-
mained wake-like in nature. Power spectral analysis indicates
that EEG activity during cataplexy is comparable to wakeful-
ness, suggesting that cortical arousal (i.e., consciousness) is
maintained during such attacks, as it is in humans [10, 11].
Cataplexy is terminated quickly (Figures 1A and 1C), with
mice resuming typical waking behaviors such as grooming,
eating, or walking. During the 6 hr recording period, narco-
leptic mice experienced 3 6 1 cataplexy episodes that each
lasted 66 6 15 s.
Cataplexy may result from the intrusion of REM sleep paral-
ysis (atonia) into waking [3]. However, it is unknown whether
postural muscles become atonic or simply experience
reduced tone during cataplexy. We quantified both masseter
and neck muscle tone during cataplexy and REM sleep paral-
ysis (Figure 1B) and found that EMG tone rapidly decreased at
cataplexy onset and returned at cataplexy offset (n = 8; before
cataplexy versus during cataplexy: H = 16.22, p < 0.01 for both
neck and masseter muscles; Figure 1C). During cataplexy,
both masseter and neck muscle tone remained at levels com-
parable to those experienced during REM sleep paralysis
(REM versus cataplexy: masseter, t = 0.497, df = 12, p =
0.663, neck, t = 72.0, p = 0.202; Figures 1B–1D).
These findings illustrate that during cataplexy narcoleptic
mice—like narcoleptic humans—experience REM-like motor
paralysis in masseter (and neck) muscles despite maintained
wakefulness. Experimentally, this means that we can use thetrigeminal motoneurons, as well as the masseter muscles
they innervate, as a model system for determining how moto-
neurons are switched off during cataplexy.
Noradrenergic System Activity Influences Cataplexy
A first step in linking noradrenergic system function with con-
trol of cataplexy is to demonstrate that cataplexy expression is
affected by changes in noradrenergic activity. Noradrenergic
receptor manipulation has been previously shown to influence
cataplexy in dogs with hypocretin-2 receptor mutations and in
humans with hypocretin cell loss [12, 13]. But, it is unknown
whether such changes also modulate cataplexy expression
in hypocretin knockout mice. To test the hypothesis that cata-
plexy is triggered by a noradrenergic mechanism, we injected
different doses of either an a1 receptor agonist (5 and 10mg/kg
phenylephrine; intraperitoneal) or antagonist (5 and 10 mg/kg
terazosin; intraperitoneal).
We found that agonism of a1 receptors reduced amounts of
cataplexy. Even though a 5 mg/kg dose of phenylephrine
reduced the total amount of cataplexy by 73% and reduced
the number of episodes by 67%, these reductions were not
statistically significant (n = 6; p > 0.05 for both variables; Fig-
ures 2A and 2B). However, 10 mg/kg phenylephrine reduced
amounts of cataplexy by 90% (n = 6; H = 9.095, df = 2, p <
0.05; Figure 2A). This decrease was caused by a 92% reduc-
tion in the number of cataplectic episodes (F = 6.2, df = 2,
p = 0.01, Figure 2B); the duration of individual episodes of cat-
aplexy was not affected by this intervention (p > 0.05; data not
shown). These findings demonstrate that a1 receptor stimula-
tion prevents cataplexy attacks and support the hypothesis
that cataplexy is mediated by a noradrenergic mechanism.
Next, we found that a1 receptor antagonism increased
cataplexy. A 5 mg/kg dose of terazosin had no effect on either
the number or duration of cataplectic episodes (n = 6; right
masseter ANOVA, p > 0.05 for both variables; Figure 2D).
But, a single injection of 10 mg/kg terazosin increased the
number of cataplectic episodes by 92% (n = 6; right masseter
ANOVA, F = 7.75, df = 2, p < 0.05; Figure 2D) despite having
no significant effect on the total amount of time spent in
cataplexy (p > 0.05; Figure 2C) or episode duration (p > 0.05;
data not shown).
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Figure 3. Loss of Noradrenergic Drive Contributes to Muscle Atonia during
Cataplexy
(A) Waking levels of left masseter muscle tone are significantly reduced by
a1 receptor antagonism (terazosin) at the left trigeminal motor pool. How-
ever, this same intervention had no effect on masseter muscle tone during
cataplexy, demonstrating that the waking noradrenergic drive is withdrawn
during cataplexy.
(B) a1 receptor manipulation at the left trigeminal motor pool affected left
masseter muscle tone but has no impact on right masseter muscle tone.
(C) Antagonism of a1 receptors on trigeminal motor neurons (by terazosin
perfusion) reduced waking masseter muscle tone, but it did not lower it to
cataplectic levels, indicating that loss of noradrenergic drive is not the
only mechanism triggering muscle atonia during cataplexy.
*p < 0.05. A.U., arbitrary units. Values are plotted as means + SEM. See also
Figure S1, which shows that drug manipulations primarily target motoneu-
rons in the left trigeminal motor pool.
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Cataplexy
Since LC neurons stop firing during cataplexy in narcoleptic
dogs, it has been hypothesized that loss of noradrenergic
drive to motoneurons underlies cataplexy [4, 14]. Therefore,
we aimed to determine (1) whether an endogenous noradren-
ergic drive at the trigeminal motor pool functions to support
postural muscle tone during normal wakefulness and (2)
whether loss of this excitatory drive tomotoneurons is respon-
sible for triggering cataplexy in narcoleptic mice.
First, we identified the presence of a functional noradren-
ergic drive onto trigeminal motoneurons that acts to support
waking muscle tone. We found that antagonism of a1 adren-
ergic receptors by terazosin perfusion (1mM) at the left trigem-
inal motor pool markedly suppressed left masseter muscle
tone during waking (artificial cerebrospinal fluid [aCSF] versusterazosin: t = 4.47, df = 3, p = 0.03). Specifically, we showed
that receptor antagonism reduced waking masseter tone by
33% in the 30 s period before cataplexy and by 31% in the
30 s period after cataplexy (before cataplexy: Z = 22.71, p <
0.01; after cataplexy: Z = 21.98, p = 0.053; Figure 3A). This
finding provides direct support for the idea that high noradren-
ergic drive to motoneurons supports waking levels of postural
tone. Importantly, applied drugs targeted the left trigeminal
motor nucleus (Figure S2) and had minimal effects of sleep-
wake architecture (Figure S3).
Drug manipulations were specifically targeted at motoneu-
rons in the left trigeminal motor pool since right masseter mus-
cle activity (before cataplexy: p > 0.05; after cataplexy: p >
0.05; Figure 3B) was unaffected by thesemanipulations. These
findings therefore suggest that suppression of waking (left)
masseter tone was the result of direct motoneuron manipula-
tion and did not result from nonspecific manipulation of the tri-
geminal interneurons that encapsulate the motor pool [15].
Second, we showed that noradrenergic drive onto trigeminal
motoneurons is lost during cataplexy episodes. Although a1
adrenergic receptor antagonism significantly reduced left
masseter tone during periods of waking immediately preced-
ing and following cataplectic attacks, this same intervention
had no effect on masseter muscle tone during discrete
cataplexy episodes (aCSF versus terazosin: Z = 20.365, p >
0.05; Figure 3A). This observation suggests that noradrenergic
excitation of motoneurons is either minimal or absent during
cataplexy and is consistent with unit recording studies
showing that noradrenergic cell activity is absent during
periods of cataplexy [4].
Although we found that a1 receptor blockade at the trigem-
inal motor pool reduced masseter muscle tone during normal
waking, it did not reduce tone to the same levels that occurred
during cataplexy (terazosin wake versus cataplexy: F = 30, df =
2, p = 0.020; Figure 3C). Together, these findings indicate that a
functional noradrenergic drive maintains waking levels of
postural muscle tone; however, it is unlikely that loss of this
drive is the only mechanism responsible for muscle paralysis
during cataplexy (see the Discussion).
Restoration of Noradrenergic Drive Rescues Muscle
Paralysis during Cataplexy
Our final goal was to determine whether muscle atonia during
cataplexy could be prevented by restoration of noradrenergic
drive onto motoneurons. However, we first wanted to deter-
mine whether activation of a1 receptors onmotoneurons could
prevent the natural loss of masseter muscle tone during sleep.
To do this, we applied the a1 receptor agonist 1 mM phenyl-
ephrine into the trigeminal motor nucleus during non-REM
and REM sleep in both wild-type and narcoleptic mice. We
found that phenylephrine perfusion prevented the normal
loss of masseter muscle tone during sleep by increasing mus-
cle tone by 13% 6 4% during non-REM sleep (n = 9; aCSF
versus phenylephrine: t = 23.83, p = 0.006) and by 12% 6
3% during REM sleep in wild-type mice (t = 23.13, p < 0.05;
Figures 4A and 4B). This same intervention increased
masseter tone by 30% 6 5% during non-REM (n = 10; aCSF
versus phenylephrine: t = 24.56, p = 0.001) sleep and by
35% 6 9% during REM sleep (t = 23.40, p = 0.008; Figures
4C and 4D) in narcoleptic mice. These results demonstrate
thatmuscle tone can be restoredwith an exogenous noradren-
ergic drive to motoneurons.
To determine whether loss of noradrenergic drive underlies
muscle atonia during cataplexy, we pharmacologically
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Figure 5. Activation of a1 Adrenergic Receptors on Motoneurons Elevates
Muscle Tone during Cataplexy
(A) EEG and EMG traces showing that muscle tone is increased by restoring
noradrenergic activity at the left trigeminal motor pool. Compared to control
(i.e., aCSF), phenylephrine perfusion onto motor neurons in the left trigem-
inal nucleus prevented atonia in the left masseter muscle during cataplexy,
but atonia persists in right masseter and neck muscles.
(B) Group data (n = 9) showing that left masseter tone is significantly
increased during cataplexy when phenylephrine is perfused at the left tri-
geminal motor pool.
(C) Group data showing that phenylephrine perfusion restored masseter
muscle tone to near waking levels during cataplexy.
*p < 0.05. A.U., arbitrary units. Values are plotted as means + SEM. See also
Figure S2, which shows that targeted drug manipulations have negligible
affects on cataplexy or sleep-wake activity.
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Figure 4. Stimulating a1 Adrenergic Receptors on Motoneurons Increases
Muscle Tone during Sleep
(A) EEG and EMG traces showing that sleeping levels of masseter muscle
tone can be reversed by stimulating a1 adrenergic receptors (via phenyleph-
rine) at the trigeminal motor pool in wild-type mice.
(B) Group data (n = 9) showing that phenylephrine perfusion (1 mM) at the
trigeminal motor pool increased masseter muscle tone during non-REM
and REM sleep in wild-type mice.
(C) EEG and EMG traces showing that stimulating a1 adrenergic receptors at
the trigeminal motor pool can also increase masseter tone during sleep in
narcoleptic mice.
(D) Group data (n = 9) showing that phenylephrine perfusion also increased
masseter muscle tone during non-REM and REM sleep in narcoleptic mice.
These results show that 1 mM phenylephrine has the ability to rescue mus-
cle tone during sleep in both wild-type and narcoleptic mice. This concen-
tration should therefore be able to restore muscle tone during cataplexy.
*p < 0.05. A.U., arbitrary units. Values are plotted as means + SEM.
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plexy. We found that activation of a1 receptors at the left
trigeminal motor pool increased left masseter tone during
cataplexy (aCSF versus phenylephrine: t test, t = 24.20 p <
0.01; Figures 5A and 5B). Specifically, we found that receptor
activation increased masseter tone by 93% 6 33% above
baseline cataplexy levels. Phenylephrine perfusion increased
left masseter muscle tone during cataplexy to levels similar
to those seen during normal waking (cataplexy aCSF versus
cataplexy phenylephrine: ANOVA on ranks, p > 0.05; Fig-
ure 5C). However, this targeted intervention had no effect on
either right masseter (p > 0.05; Figure 5B) or neck (p > 0.05;
data not shown) muscle tone. Muscle atonia in both muscle
groups remained intact during cataplexy, illustrating that
drugmanipulation primarily influencedmotoneurons in the tar-
geted motor pool.
Discussion
Postural muscle tone is needed to support routine motor
behaviors. Despite its obvious behavioral importance, it was
unknown how postural muscle tone and brain arousal state
are functionally coupled. Here, we demonstrate that the norad-
renergic system acts to synchronize motor and arousal sys-
tems by facilitating skeletal motoneuron activity and hence
muscle tone during wakefulness. Loss of this normal excit-
atory drive decouples these systems, thus resulting in motoratonia during otherwise normal wakefulness, as is seen in cat-
aplexy. Our data suggest that loss of hypocretin could trigger
motor atonia by influencing noradrenergic system function.
The Noradrenergic System Functions to Promote Waking
Postural Motor Tone
The noradrenergic system has long been considered impor-
tant in controlling muscle tone. Stimulation of brainstem
noradrenergic cells (e.g., LC cells) in anaesthetized or decere-
brate animals can facilitate motoneuron activity by a a1-recep-
tor-mediated mechanism [6, 7, 16–18]. Although this shows
the noradrenergic system modulates muscle tone, it does
not demonstrate that it promotes motor activity during actual
behaviors. Support for this view comes from unit recording
studies showing that noradrenergic cell activity is tightly corre-
lated to levels of muscle tone; e.g., locus coeruleus cells fire
maximally when muscle tone is high and minimally when it is
Noradrenergic Control of Postural Muscle Tone
1723low [9]. These studies are clouded by the fact that cell
discharge rates also correlate with arousal state, thus making
it difficult to determine whether their activity reflects levels of
muscle tone, behavioral state, or both. Perhaps the strongest
evidence suggesting that a noradrenergic mechanism under-
lies postural tone stems from quantitative studies showing
that levels of noradrenaline within spinal/cranial motor pools
is broadly proportional to levels of muscle tone [19]. Noradren-
aline may excite motoneurons by a direct a1-receptor-medi-
ated mechanism or by facilitating persistent inward currents
or potentially by amplifying glutamatergic drive ontomotoneu-
rons [20, 21].
Our current data show that postural muscle tone is indeed
controlled by a noradrenergic mechanism duringwakefulness.
Specifically, we show that a functional noradrenergic drive
triggers postural muscle tone by stimulating a1 receptors on
motoneurons. A similar type of noradrenergic mechanism
has been previously shown to underlie more specializedmotor
behaviors: a noradrenergic drive acting on respiratory moto-
neurons is responsible for regulating the so-called ‘‘wakeful-
ness stimulus to breathe’’ [7], and loss of this drive is thought
to underlie reduced respiratory muscle activity during REM-
like sleep [16]. Collectively, these data show the noradrenergic
system is pivotal in controlling levels ofmuscle tone in different
motor systems.
Loss of Noradrenergic Drive Underlies Cataplexy
A longstanding hypothesis is that cataplexy is triggered by
loss of noradrenergic system activity, but direct evidence for
this idea was lacking [4, 14]. Here, we show that withdrawal
of a functional noradrenergic drive to trigeminal motoneurons
underlies masseter muscle paralysis during cataplexy. This
excitatory drive is present during the waking periods immedi-
ately before and after cataplexy but is rapidly withdrawn dur-
ing cataplectic attacks.
Our data are consistent with studies in narcoleptic dogs
showing that cell activity in the LC is correlated with cataplexy
[4, 14]. Unit recordings show that cell activity ismaximal imme-
diately before and after cataplectic attacks but falls silent
during attacks, suggesting that noradrenergic system inac-
tivity triggers motor atonia during cataplexy. Our data provide
support for this observation by showing that noradrenergic
drive to motoneurons is either lost or minimal during cataplexy
in narcoleptic mice.
It is debatable whether LC cell inactivity itself causes motor
paralysis during cataplexy. Although these cells stop firing
during cataplexy, they send relatively few direct projections
to skeletal motoneurons [22]. Other sources of noradrenergic
drive to motoneurons could be from A5 and/or A7 cell groups
[22, 23]. It is unknown whether inactivity of these cells pro-
mote cataplexy, but A5 cells stop firing during REM-like sleep
[24, 25], suggesting that their inactivity promotes muscle
atonia.
A noradrenergic mechanism is not uniquely responsible
for triggering cataplexy. We found that antagonization of a1
receptors on motoneurons markedly suppressed postural
tone, but it did not induce completemotor paralysis, indicating
that additional mechanisms are involved. Unit recordings from
brainstem cells show that serotonin cell activity is reduced and
GABA/glycine cell activity is increased during cataplexy in
narcoleptic dogs [26, 27]. This observation implies that
reduced serotonin excitation and increased GABA/glycine
inhibition could also contribute to loss of motor tone during
cataplexy.Increasing Noradrenergic Drive Rescues Cataplexy
Drugs that boost noradrenergic system activity are used to
treat cataplexy. Tricyclic antidepressants—which elevate
CNS levels of noradrenaline—are effective in reducing cata-
plexy in narcoleptic people, dogs, and mice [12, 28–33].
Although tricyclics influence a variety of transmitter systems
(e.g., serotonin), they are thought to mediate their affects on
cataplexy by a noradrenergic mechanism [34]. Pharmacolog-
ical studies show that selective noradrenergic receptor manip-
ulation effects cataplexy in narcoleptic dogs [12, 34, 35].
Our data indicate that cataplexy results from functional loss
of noradrenergic drive. We therefore hypothesize that tricyclic
antidepressants and noradrenergic reuptake inhibitors may
exert their actions by restoring this drive. Specifically, we
suggest that they act to increase noradrenaline, which func-
tions to protect motoneurons from the drop in noradrenergic
drive during cataplexy. Our pharmacological studies show
that boosting noradrenergic drive prevents cataplexy,
whereas decreasing drive exacerbates it. But, more impor-
tantly, we show that direct restoration of noradrenergic drive
to motoneurons prevents motor paralysis during cataplexy.
Both of these findings support our assertion that (1) cataplexy
results from loss of noradrenergic drive and (2) that rescue of
this lost drive prevents cataplexy.
Hypocretin Deficiency Impacts Noradrenergic System
Function
Hypocretin deficiency underlies cataplexy since hypocretin
cell loss, inability to produce hypocretin, and dysfunctional
hypocretin receptors can trigger cataplexy in humans, dogs,
rats, andmice [10, 11, 36–40]. However, it is unclear how hypo-
cretin system dysfunction causes cataplexy. Our work sug-
gests that hypocretin deficiency could trigger cataplexy by
disrupting normal noradrenergic system function.
There are strong connections between the hypocretin and
noradrenergic systems. For example, hypocretin cells send
dense projects to noradrenergic cells, and particularly those
in the LC. Noradrenergic cells also express hypocretin recep-
tors and are markedly excited by hypocretin application.
Furthermore, hypocretin levels in the LC influence noradren-
ergic release onto target sites [41]. Together, these findings
suggest that noradrenergic activity is tightly controlled by
the hypocretin system.
Our data indicate that a faulty noradrenergic signaling
mechanism underlies cataplexy in hypocretin knockout mice,
suggesting that hypocretin deficiency perturbs normal norad-
renergic system function. We propose that waking postural
muscle tone is supported by the combined actions of hypocre-
tin and noradrenergic system activity (Figures 6A and 6B). In
healthy people, hypocretin facilitates postural tone directly
and by driving noradrenergic release onto motoneurons. But
in narcolepsy, hypocretin drive is lost, which reduces norad-
renergic activity and hence excitation of skeletalmotoneurons,
thus resulting in cataplexy (Figure 6C).
But, why is cataplexy generally triggered by strong positive
emotions or rewarding stimuli? The hypocretin system is most
active during situations normally associated with cataplexy in
narcoleptics. For example, hypocretin release is maximal dur-
ing social interactions in nonnarcoleptic humans [42], and
hypocretin cell activity is highest during novel conditions in
rats [43]. Therefore, hypocretin deficiency would be expected
to tip the normal balance of noradrenergic excitation during
situations associated with cataplexy, thus leading to lapses
in noradrenergic drive to motoneurons and hence cataplexy.
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Figure 6. The Role for the Noradrenergic System in Coupling Arousal and
Muscle Tone
Under normal waking conditions, hypocretin neurons (Hcrt) are active,
providing excitatory inputs to noradrenergic (NA) and histaminergic (HA)
neurons; this in turn helps maintain both waking muscle tone and arousal.
During sleep, while both arousal and muscle tone are low, all three cell
groups fall silent. During cataplexy, muscle tone is absent, but arousal
and consciousness are intact. This decoupling of arousal state and appro-
priate levels of muscle tone is mirrored by the continued activity of hista-
mine neurons while noradrenaline neurons fall silent, suggesting that the
noradrenergic system acts to facilitate normal waking muscle tone while
histamine acts to support consciousness. Noradrenergic excitation of mus-
cle tone could be via direct excitation of spinal motor neurons (from A5, the
LC, and A7) or indirect through brainstem circuits that regulate muscle tone.
This schematic does not include several nuclei that have been demon-
strated to play a role in muscle tone or cortical arousal, including cholin-
ergic, dopaminergic, and serotonergic nuclei, but demonstrates how these
behaviors can be decoupled under specific conditions such as cataplexy.
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Arousal Systems
This study provides a new framework for understanding how
the noradrenergic system controls normal physiology and
behavior. First, it shows that one of its functions is to control
levels of postural motor tone during wakefulness. Second, it
shows that loss of noradrenergic system activity results in
motor atonia during otherwise normal wakefulness (i.e., cata-
plexy). Together, these observations indicate that the norad-
renergic system functions to synchronize motor and arousal
behaviors.
The noradrenergic system has been hypothesized to control
behavioral arousal state. For example, optogenetic activationof noradrenergic cells in the LC can stimulate behavioral
arousal from sleep [44]. However, some studies have ques-
tioned the role of the noradrenergic system in mediating
arousal. Unit recording studies in narcoleptic dogs show that
during cataplexy LC cells stop firing, but tuberomamillary his-
taminergic neurons do not [14]. This suggests that the hista-
minergic system is primarily responsible for promoting
arousal, whereas the noradrenergic system functions to sup-
port postural muscle tone; although other transmitter systems
are also involved in both arousal and muscle tone.
Recent optogenetic studies also support our assertion that
the noradrenergic system acts to synchronize motor and
arousal behaviors. Overstimulation of the LC caused depletion
of their noradrenergic stores and hence release, which led to
rapid onset of behavioral arrests in wild-type mice [44]. These
arrests were similar to the cataplexy attacks because they
were marked by postural collapse during wakefulness. These
findings not only support our view that cataplexy results
from reduced noradrenergic drive to motoneurons, but also
suggest that the noradrenergic system functions to couple
motor behavior with arousal state.
Experimental Procedures
All studies were carried out in accordance with the Canadian Council on
Animal Care and approved by the Animal Care Committee at the University
of Toronto. Previously described protocols were used for (1) instrumenta-
tion of mice with electrophysiological electrodes for sleep-wake behaviors
and cataplexy [45, 46] and (2) selective application of transmitter agonists
or antagonists to target brain regions [47, 48]. A complete description of
these and other materials and methods are available in the Supplemental
Experimental Procedures.
Supplemental Information
Supplemental Information includes Supplemental Experimental Proce-
dures, two figures, and one movie and can be found with this article online
at http://dx.doi.org/10.1016/j.cub.2013.07.014.
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